Heart Failure With Preserved Ejection Fraction

Current Problems in Cardiology

Volumn 41, Issue 4, 2016, Pages 145-188

  Reddy, Yogesh N V ^a   Borlaug, Barry A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISOSORBIDE MONONITRATE; IVABRADINE; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; PERINDOPRIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; ROSUVASTATIN; SACUBITRIL; SERELAXIN; SILDENAFIL; SODIUM NITRATE; SPIRONOLACTONE;

ACUTE HEART FAILURE; ARTICLE; ATRIAL FIBRILLATION; CLINICAL EXAMINATION; COMORBIDITY; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART CATHETERIZATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE SIZE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY HYPERTENSION; SODIUM RESTRICTION; SYSTOLIC DYSFUNCTION; ANIMAL; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MORTALITY; TREATMENT OUTCOME;

ANIMALS; HEART FAILURE; HUMANS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84964318210     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2015.12.002     Document Type: Article

References (228)

1. 1 Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
2. 2 Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
3. 3 Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126 (2012), 65–75.
4. 4 Bursi, F., Weston, S.A., Redfield, M.M., et al. Systolic and diastolic heart failure in the community. J Am Med Assoc 296 (2006), 2209–2216.
5. 5 Borlaug, B.A., Paulus, W.J., Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32 (2011), 670–679.
6. 6 Gurwitz, J.H., Magid, D.J., Smith, D.H., et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med 126 (2013), 393–400.
7. 7 Andersen, M.J., Borlaug, B.A., Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep, 16, 2014, 501.
8. 8 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
9. 9 Schwartzenberg, S., Redfield, M.M., From, A.M., Sorajja, P., Nishimura, R.A., Borlaug, B.A., Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59 (2012), 442–451.
10. 10 Solomon, S.D., Vasodilators across the heart failure spectrum not all patients, and not all vasodilators, are created equal. J Am Coll Cardiol 59 (2012), 452–454.
11. 11 Borlaug, B.A., Redfield, M.M., Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123 (2011), 2006–2013 [discussion 2014].
12. 12 Abudiab, M.M., Redfield, M.M., Melenovsky, V., et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 15 (2013), 776–785.
13. 13 Bhatia, R.S., Tu, J.V., Lee, D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
14. 14 Kitzman, D.W., Little, W.C., Brubaker, P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. J Am Med Assoc 288 (2002), 2144–2150.
15. 15 Yancy, C.W., Lopatin, M., Stevenson, L.W., De Marco, T., Fonarow, G.C., Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 47 (2006), 76–84.
16. 16 Fonarow, G.C., Stough, W.G., Abraham, W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007), 768–777.
17. 17 Sweitzer, N.K., Lopatin, M., Yancy, C.W., Mills, R.M., Stevenson, L.W., Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol 101 (2008), 1151–1156.
18. 18 Basuray, A., French, B., Ky, B., et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 129 (2014), 2380–2387.
19. 19 Solomon, S.D., Claggett, B., Lewis, E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure and preserved ejection fraction. Eur Heart J, 2016 [in press].
20. 20 Borlaug, B.A., Heart failure with preserved ejection fraction: where do we draw the line. Eur Heart J, 2016 [in presss].
21. 21 De Keulenaer, G.W., Brutsaert, D.L., The heart failure spectrum: time for a phenotype-oriented approach. Circulation 119 (2009), 3044–3046.
22. 22 De Keulenaer, G.W., Brutsaert, D.L., Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 123 (2011), 1996–2005.
23. 23 Cohn, J.N., Ferrari, R., Sharpe, N., Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 (2000), 569–582.
24. 24 van Heerebeek, L., Borbely, A., Niessen, H.W., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 (2006), 1966–1973.
25. 25 Iwanaga, Y., Nishi, I., Furuichi, S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47 (2006), 742–748.
26. 26 Borlaug, B.A., Nishimura, R.A., Sorajja, P., Lam, C.S., Redfield, M.M., Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 3 (2010), 588–595.
27. 27 Anjan, V.Y., Loftus, T.M., Burke, M.A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 110 (2012), 870–876.
28. 28 Kawaguchi, M., Hay, I., Fetics, B., Kass, D.A., Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107 (2003), 714–720.
29. 29 Borlaug, B.A., Lam, C.S., Roger, V.L., Rodeheffer, R.J., Redfield, M.M., Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54 (2009), 410–418.
30. 30 Shah, S.J., Katz, D.H., Selvaraj, S., et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131 (2015), 269–279.
31. 31 Sanderson, J.E., Gibson, D.G., Brown, D.J., Goodwin, J.F., Left ventricular filling in hypertrophic cardiomyopathy. An angiographic study. Br Heart J 39 (1977), 661–670.
32. 32 Topol, E.J., Traill, T.A., Fortuin, N.J., Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 31 (1985), 277–283.
33. 33 Zile, M.R., Gaasch, W.H., Carroll, J.D., et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure. Circulation 104 (2001), 779–782.
34. 34 Persson, H., Lonn, E., Edner, M., et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 49 (2007), 687–694.
35. 35 Shah, A.M., Shah, S.J., Anand, I.S., et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 7 (2014), 104–115.
36. 36 Zile, M.R., Gottdiener, J.S., Hetzel, S.J., et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 (2011), 2491–2501.
37. 37 Borlaug, B.A., Melenovsky, V., Russell, S.D., et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114 (2006), 2138–2147.
38. 38 Tan, Y.T., Wenzelburger, F., Lee, E., et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 54 (2009), 36–46.
39. 39 Phan, T.T., Abozguia, K., Nallur Shivu, G., et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 54 (2009), 402–409.
40. 40 Lam, C.S., Roger, V.L., Rodeheffer, R.J., Borlaug, B.A., Enders, F.T., Redfield, M.M., Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53 (2009), 1119–1126.
41. 41 Borlaug, B.A., Olson, T.P., Lam, C.S., et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56 (2010), 845–854.
42. 42 Prasad, A., Hastings, J.L., Shibata, S., et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail 3 (2010), 617–626.
43. 43 Haykowsky, M.J., Brubaker, P.H., John, J.M., Stewart, K.P., Morgan, T.M., Kitzman, D.W., Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 58 (2011), 265–274.
44. 44 Shibata, S., Hastings, J.L., Prasad, A., et al. Congestive heart failure with preserved ejection fraction is associated with severely impaired dynamic Starling mechanism. J Appl Physiol 110 (2011), 964–971.
45. 45 Bhella, P.S., Prasad, A., Heinicke, K., et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail 13 (2011), 1296–1304.
46. 46 Borlaug, B.A., Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J 78 (2013), 20–32.
47. 47 Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 7 (2014), 740–751.
48. 48 Santos, A.B., Kraigher-Krainer, E., Gupta, D.K., et al. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail 16 (2014), 1096–1103.
49. 49 Santos, A.B., Kraigher-Krainer, E., Bello, N., et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 35 (2014), 42–47.
50. 50 Kraigher-Krainer, E., Shah, A.M., Gupta, D.K., et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63 (2014), 447–456.
51. 51 Burke, M.A., Katz, D.H., Beussink, L., et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail 7 (2014), 288–299.
52. 52 Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132 (2015), 402–414.
53. 53 Melenovsky, V., Hwang, S.J., Redfield, M.M., Zakeri, R., Lin, G., Borlaug, B.A., Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 8 (2015), 295–303.
54. 54 Andersen, M.J., Hwang, S.J., Kane, G.C., et al. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail 8 (2015), 542–550.
55. 55 Zakeri, R., Borlaug, B.A., McNulty, S.E., et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 7 (2014), 123–130.
56. 56 van Empel, V.P., Mariani, J., Borlaug, B.A., Kaye, D.M., Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc, 3, 2014, e001293.
57. 57 Melenovsky, V., Hwang, S.J., Lin, G., Redfield, M.M., Borlaug, B.A., Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35 (2014), 3452–3462.
58. 58 Borlaug, B.A., The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 11 (2014), 507–515.
59. 59 Melenovsky, V., Borlaug, B.A., Rosen, B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 49 (2007), 198–207.
60. 60 Santos, M., Opotowsky, A.R., Shah, A.M., Tracy, J., Waxman, A.B., Systrom, D.M., Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction. Circ Heart Fail 8 (2015), 278–285.
61. 61 Kitzman, D.W., Nicklas, B., Kraus, W.E., et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 306 (2014), H1364–H1370.
62. 62 Haykowsky, M.J., Kouba, E.J., Brubaker, P.H., Nicklas, B.J., Eggebeen, J., Kitzman, D.W., Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol 113 (2014), 1211–1216.
63. 63 Kusunose, K., Motoki, H., Popovic, Z.B., Thomas, J.D., Klein, A.L., Marwick, T.H., Independent association of left atrial function with exercise capacity in patients with preserved ejection fraction. Heart 98 (2012), 1311–1317.
64. 64 Go, A.S., Mozaffarian, D., Roger, V.L., et al. Heart disease and stroke statistics-—2014 update: a report from the American Heart Association. Circulation 129 (2014), e28–e292.
65. 65 Brouwers, F.P., de Boer, R.A., van der Harst, P., et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34 (2013), 1424–1431.
66. 66 Mentz, R.J., Kelly, J.P., von Lueder, T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64 (2014), 2281–2293.
67. 67 Mohammed, S.F., Borlaug, B.A., Roger, V.L., et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 5 (2012), 710–719.
68. 68 Campbell, R.T., Jhund, P.S., Castagno, D., Hawkins, N.M., Petrie, M.C., McMurray, J.J., What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE. J Am Coll Cardiol 60 (2012), 2349–2356.
69. 69 Ho, J.E., Lyass, A., Lee, D.S., et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail, 2012.
70. 70 Lam, C.S., Lyass, A., Kraigher-Krainer, E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 124 (2011), 24–30.
71. 71 Kane, G.C., Karon, B.L., Mahoney, D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. J Am Med Assoc 306 (2011), 856–863.
72. 72 Fujimoto, N., Hastings, J.L., Bhella, P.S., et al. Effect of ageing on left ventricular compliance and distensibility in healthy sedentary humans. J Physiol 590 (2012), 1871–1880.
73. 73 Carrick-Ranson, G., Hastings, J.L., Bhella, P.S., et al. Effect of healthy aging on left ventricular relaxation and diastolic suction. Am J Physiol Heart Circ Physiol 303 (2012), H315–H322.
74. 74 Borlaug, B.A., Redfield, M.M., Melenovsky, V., et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail 6 (2013), 944–952.
75. 75 Wohlfahrt, P., Redfield, M.M., Lopez-Jimenez, F., et al. Impact of general and central adiposity of ventricular-arterial aging in women and men. JACC Heart Fail, 2014 [in press].
76. 76 Niemann, B., Chen, Y., Teschner, M., Li, L., Silber, R.E., Rohrbach, S., Obesity induces signs of premature cardiac aging in younger patients: the role of mitochondria. J Am Coll Cardiol 57 (2011), 577–585.
77. 77 Pandey, A., Garg, S., Khunger, M., et al. Dose response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation, 2015.
78. 78 Kraigher-Krainer, E., Lyass, A., Massaro, J.M., et al. Association of physical activity and heart failure with preserved vs. reduced ejection fraction in the elderly: the Framingham Heart Study. Eur J Heart Fail 15 (2013), 742–746.
79. 79 Brinker, S.K., Pandey, A., Ayers, C.R., et al. Association of cardiorespiratory fitness with left ventricular remodeling and diastolic function: the Cooper Center Longitudinal Study. JACC Heart Fail 2 (2014), 238–246.
80. 80 Lee, D.S., Gona, P., Vasan, R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 119 (2009), 3070–3077.
81. 81 Hwang, S.J., Melenovsky, V., Borlaug, B.A., Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 63 (2014), 2817–2827.
82. 82 (MAGGIC) M-aGGiCHF, The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33 (2012), 1750–1757.
83. 83 Zile, M.R., Gaasch, W.H., Anand, I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 121 (2010), 1393–1405.
84. 84 Lee, D.S., Gona, P., Albano, I., et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 4 (2011), 36–43.
85. 85 Henkel, D.M., Redfield, M.M., Weston, S.A., Gerber, Y., Roger, V.L., Death in heart failure: a community perspective. Circ Heart Fail 1 (2008), 91–97.
86. 86 Borlaug, B.A., Jaber, W.A., Ommen, S.R., Lam, C.S., Redfield, M.M., Nishimura, R.A., Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 97 (2011), 964–969.
87. 87 Flachskampf, F.A., Biering-Sorensen, T., Solomon, S.D., Duvernoy, O., Bjerner, T., Smiseth, O.A., Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging 8 (2015), 1071–1093.
88. 88 Maurer, M.S., Spevack, D., Burkhoff, D., Kronzon, I., Diastolic dysfunction: can it be diagnosed by Doppler echocardiography?. J Am Coll Cardiol 44 (2004), 1543–1549.
89. 89 Bhella, P.S., Pacini, E.L., Prasad, A., et al. Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging, 2011.
90. 90 Santos, M., Rivero, J., McCullough, S.D., et al. E/e’ ratio in patients with unexplained dyspnea: lack of accuracy in estimating left ventricular filling pressure. Circ Heart Fail 8 (2015), 749–756.
91. 91 Borlaug, B.A., Koepp, K.E., Melenovsky, V., Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 66 (2015), 1672–1682.
92. 92 Andersen, M.J., Olson, T.P., Melenovsky, V., Kane, G.C., Borlaug, B.A., Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 8 (2015), 41–48.
93. 93 Maeder, M.T., Thompson, B.R., Brunner-La Rocca, H.P., Kaye, D.M., Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 56 (2010), 855–863.
94. 94 Dhakal, B.P., Malhotra, R., Murphy, R.M., et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail 8 (2015), 286–294.
95. 95 Zile, M.R., Baicu, C.F., Gaasch, W.H., Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004), 1953–1959.
96. 96 Wachter, R., Schmidt-Schweda, S., Westermann, D., et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 30 (2009), 3027–3036.
97. 97 Hay, I., Rich, J., Ferber, P., Burkhoff, D., Maurer, M.S., Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 288 (2005), H1203–H1208.
98. 98 Redfield, M.M., Jacobsen, S.J., Burnett, J.C. Jr., Mahoney, D.W., Bailey, K.R., Rodeheffer, R.J., Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. J Am Med Assoc 289 (2003), 194–202.
99. 99 Aljaroudi, W., Alraies, M.C., Halley, C., et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 125 (2012), 782–788.
100. 100 Borlaug, B.A., Kass, D.A., Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 16 (2006), 273–279.
101. 101 Sharma, K., Kass, D.A., Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 115 (2014), 79–96.
102. 102 Bers, D.M., Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70 (2008), 23–49.
103. 103 Selby, D.E., Palmer, B.M., Lewinter, M.M., Meyer, M., Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 58 (2011), 147–154.
104. 104 Kass, D.A., Assessment of diastolic dysfunction: invasive modalities. Cardiol Clin 18 (2000), 571–586.
105. 105 Leite-Moreira, A.F., Correia-Pinto, J., Load as an acute determinant of end-diastolic pressure-volume relation. Am J Physiol Heart Circ Physiol 280 (2001), H51–H59.
106. 106 Gillebert, T.C., Leite-Moreira, A.F., De Hert, S.G., Load dependent diastolic dysfunction in heart failure. Heart Fail Rev 5 (2000), 345–355.
107. 107 Gillebert, T.C., Leite-Moreira, A.F., De Hert, S.G., Relaxation-systolic pressure relation. A load-independent assessment of left ventricular contractility. Circulation 95 (1997), 745–752.
108. 108 Takimoto, E., Soergel, D.G., Janssen, P.M., Stull, L.B., Kass, D.A., Murphy, A.M., Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res 94 (2004), 496–504.
109. 109 Popovic, Z.B., Prasad, A., Garcia, M.J., et al. Relationship among diastolic intraventricular pressure gradients, relaxation, and preload: impact of age and fitness. Am J Physiol Heart Circ Physiol 290 (2006), H1454–H1459.
110. 110 Opdahl, A., Remme, E.W., Helle-Valle, T., Edvardsen, T., Smiseth, O.A., Myocardial relaxation, restoring forces, and early-diastolic load are independent determinants of left ventricular untwisting rate. Circulation 126 (2012), 1441–1451.
111. 111 Opdahl, A., Remme, E.W., Helle-Valle, T., et al. Determinants of left ventricular early-diastolic lengthening velocity: independent contributions from left ventricular relaxation, restoring forces, and lengthening load. Circulation 119 (2009), 2578–2586.
112. 112 Ohara, T., Niebel, C.L., Stewart, K.C., et al. Loss of adrenergic augmentation of diastolic intra-LV pressure difference in patients with diastolic dysfunction: evaluation by color M-mode echocardiography. JACC Cardiovasc Imaging 5 (2012), 861–870.
113. 113 Gandhi, S.K., Powers, J.C., Nomeir, A.M., et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344 (2001), 17–22.
114. 114 van Heerebeek, L., Hamdani, N., Falcao-Pires, I., et al. Low myocardial protein kinase g activity in heart failure with preserved ejection fraction. Circulation 126 (2012), 830–839.
115. 115 Borbely, A., Falcao-Pires, I., van Heerebeek, L., et al. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 104 (2009), 780–786.
116. 116 van Heerebeek, L., Hamdani, N., Handoko, M.L., et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 (2008), 43–51.
117. 117 Zile, M.R., Baicu, C.F., Ikonomidis, J.S., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
118. 118 Borbely, A., van der Velden, J., Papp, Z., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111 (2005), 774–781.
119. 119 Yu, C.M., Lin, H., Yang, H., Kong, S.L., Zhang, Q., Lee, S.W., Progression of systolic abnormalities in patients with isolated diastolic heart failure and diastolic dysfunction. Circulation 105 (2002), 1195–1201.
120. 120 Liu, C.P., Ting, C.T., Lawrence, W., Maughan, W.L., Chang, M.S., Kass, D.A., Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants. Circulation 88 (1993), 1893–1906.
121. 121 Norman, H.S., Oujiri, J., Larue, S.J., Chapman, C.B., Margulies, K.B., Sweitzer, N.K., Decreased cardiac functional reserve in heart failure with preserved systolic function. J Card Fail 17 (2011), 301–308.
122. 122 Smith, C.S., Bottomley, P.A., Schulman, S.P., Gerstenblith, G., Weiss, R.G., Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114 (2006), 1151–1158.
123. 123 Mohammed, S.F., Hussain, S., Mirzoyev, S.A., Edwards, W.D., Maleszewski, J.J., Redfield, M.M., Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
124. 124 Kosmala, W., Rojek, A., Przewlocka-Kosmala, M., Mysiak, A., Karolko, B., Marwick, T.H., Contributions of recruitable contractility, ventriculo-arterial coupling reserve, and reduced chronotropic response to exercise intolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 62:15 (2013), 1330–1338.
125. 125 Guazzi, M., Borlaug, B.A., Pulmonary hypertension due to left heart disease. Circulation 126 (2012), 975–990.
126. 126 Pietra, G.G., Capron, F., Stewart, S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 (2004), 25 S–32 S.
127. 127 Tedford, R.J., Hassoun, P.M., Mathai, S.C., et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 125 (2012), 289–297.
128. 128 Mohammed, S.F., Hussain, I., Abou Ezzeddine, O.F., et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 130 (2014), 2310–2320.
129. 129 Chatterjee, N.A., Steiner, J., Lewis, G.D., It is time to look at heart failure with preserved ejection fraction from the right side. Circulation 130 (2014), 2272–2277.
130. 130 Borlaug, B.A., Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J 78 (2014), 20–32.
131. 131 Higginbotham, M.B., Morris, K.G., Williams, R.S., McHale, P.A., Coleman, R.E., Cobb, F.R., Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res 58 (1986), 281–291.
132. 132 Brubaker, P.H., Kitzman, D.W., Chronotropic incompetence: causes, consequences, and management. Circulation 123 (2011), 1010–1020.
133. 133 Brubaker, P.H., Joo, K.C., Stewart, K.P., Fray, B., Moore, B., Kitzman, D.W., Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 26 (2006), 86–89.
134. 134 Phan, T.T., Nallur Shivu, G., Abozguia, K., et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 3 (2009), 29–34.
135. 135 Funakoshi, K., Hosokawa, K., Kishi, T., Ide, T., Sunagawa, K., Striking volume intolerance is induced by mimicking arterial baroreflex failure in normal left ventricular function. J Card Fail 20 (2014), 53–59.
136. 136 Zakeri, R., Chamberlain, A.M., Roger, V.L., Redfield, M.M., Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128 (2013), 1085–1093.
137. 137 Phan, T.T., Abozguia, K., Shivu, G.N., et al. Increased atrial contribution to left ventricular filling compensates for impaired early filling during exercise in heart failure with preserved ejection fraction. J Card Fail 15 (2009), 890–897.
138. 138 Tan, Y.T., Wenzelburger, F., Lee, E., et al. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart 96 (2010), 1017–1023.
139. 139 Lee, A.P., Song, J.K., Yip, G.W., et al. Importance of dynamic dyssynchrony in the occurrence of hypertensive heart failure with normal ejection fraction. Eur Heart J 31 (2010), 2642–2649.
140. 140 Brutsaert, D.L., Sys, S.U., Relaxation and diastole of the heart. Physiol Rev 69 (1989), 1228–1315.
141. 141 Yu, C.M., Zhang, Q., Yip, G.W., et al. Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition. J Am Coll Cardiol 49 (2007), 97–105.
142. 142 Hundley, W.G., Kitzman, D.W., Morgan, T.M., et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38 (2001), 796–802.
143. 143 Tartiere-Kesri, L., Tartiere, J.M., Logeart, D., Beauvais, F., Cohen Solal, A., Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 59 (2012), 455–461.
144. 144 Kitzman, D.W., Herrington, D.M., Brubaker, P.H., Moore, J.B., Eggebeen, J., Haykowsky, M.J., Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension 61 (2013), 112–119.
145. 145 Borlaug, B.A., Melenovsky, V., Kass, D.A., Ventricular-arterial interaction in patients with heart failure and a preserved ejection fraction. Klein, A.L., Garcia, M., (eds.) Diastology: Clinical Approach to Diastolic Heart Failure, 1st ed, 2008, Saunders, Elsevier, Philadelphia.
146. 146 De Tombe, P.P., Jones, S., Burkhoff, D., Hunter, W.C., Kass, D.A., Ventricular stroke work and efficiency both remain nearly optimal despite altered vascular loading. Am J Physiol 264 (1993), H1817–H1824.
147. 147 Chen, C.H., Nakayama, M., Nevo, E., Fetics, B.J., Maughan, W.L., Kass, D.A., Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 32 (1998), 1221–1227.
148. 148 Borlaug, B.A., Kass, D.A., Ventricular-vascular interaction in heart failure. Heart Fail Clin 4 (2008), 23–36.
149. 149 Scantlebury, D.C., Borlaug, B.A., Why are women more likely than men to develop heart failure with preserved ejection fraction. Curr Opin Cardiol 26 (2011), 562–568.
150. 150 Little, W.C., Borlaug, B.A., Exercise intolerance in heart failure with preserved ejection fraction: what does the heart have to do with it. Circ Heart Fail 8 (2015), 233–235.
151. 151 Kitzman, D.W., Upadhya, B., Vasu, S., What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. Circulation 131 (2015), 522–524.
152. 152 Kitzman, D.W., Brubaker, P.H., Morgan, T.M., Stewart, K.P., Little, W.C., Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 3 (2010), 659–667.
153. 153 Haykowsky, M.J., Brubaker, P.H., Stewart, K.P., Morgan, T.M., Eggebeen, J., Kitzman, D.W., Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol 60 (2012), 120–128.
154. 154 Edelmann, F., Gelbrich, G., Dungen, H.D., et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58 (2011), 1780–1791.
155. 155 Akiyama, E., Sugiyama, S., Matsuzawa, Y., et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 60 (2012), 1778–1786.
156. 156 Farrero, M., Blanco, I., Batlle, M., et al. Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail 7 (2014), 791–798.
157. 157 Marechaux, S., Samson, R., van Belle, E., et al. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J Card Fail, 2015.
158. 158 Kitzman, D.W., Brubaker, P.H., Herrington, D.M., et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol 62 (2013), 584–592.
159. 159 Haykowsky, M.J., Herrington, D.M., Brubaker, P.H., Morgan, T.M., Hundley, W.G., Kitzman, D.W., Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci 68 (2013), 161–167.
160. 160 Hundley, W.G., Bayram, E., Hamilton, C.A., et al. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Am J Physiol Heart Circ Physiol 292 (2007), H1427–H1434.
161. 161 Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
162. 162 Solomon, S.D., Zile, M., Pieske, B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
163. 163 Redfield, M.M., Chen, H.H., Borlaug, B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. J Am Med Assoc 309 (2013), 1268–1277.
164. 164 Greene, S.J., Gheorghiade, M., Borlaug, B.A., et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc, 2, 2013, e000536.
165. 165 Pieske, B., Butler, J., Filippatos, G., et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 16 (2014), 1026–1038.
166. 166 Redfield, M.M., Anstrom, K.J., Levine, J.A., et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med, 2015.
167. 167 Zamani, P., Rawat, D., Shiva-Kumar, P., et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 131:4 (2015), 371–380 [discussion 380].
168. 168 Paulus, W.J., Tschope, C., Sanderson, J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007), 2539–2550.
169. 169 Drazner, M.H., Prasad, A., Ayers, C., et al. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail 3 (2010), 202–206.
170. 170 From, A.M., Lam, C.S., Pitta, S.R., et al. Bedside assessment of cardiac hemodynamics: the impact of noninvasive testing and examiner experience. Am J Med 124 (2011), 1051–1057.
171. 171 Drazner, M.H., Hellkamp, A.S., Leier, C.V., et al. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail 1 (2008), 170–177.
172. 172 McKee, P.A., Castelli, W.P., McNamara, P.M., Kannel, W.B., The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971), 1441–1446.
173. 173 Fujimoto, N., Borlaug, B.A., Lewis, G.D., et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation 127 (2013), 55–62.
174. 174 Caruana, L., Petrie, M.C., Davie, A.P., McMurray, J.J., Do patients with suspected heart failure and preserved left ventricular systolic function suffer from diastolic heart failure or from misdiagnosis? A prospective descriptive study. Br Med J 321 (2000), 215–218.
175. 175 Lam, C.S., Roger, V.L., Rodeheffer, R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115 (2007), 1982–1990.
176. 176 Ommen, S.R., Nishimura, R.A., Appleton, C.P., et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 102 (2000), 1788–1794.
177. 177 Pellicori, P., Carubelli, V., Zhang, J., et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6 (2013), 16–28.
178. 178 Little, W.C., Oh, J.K., Echocardiographic evaluation of diastolic function can be used to guide clinical care. Circulation 120 (2009), 802–809.
179. 179 Komajda, M., Carson, P.E., Hetzel, S., et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 4 (2011), 27–35.
180. 180 Cleland, J.G., Taylor, J., Tendera, M., Prognosis in heart failure with a normal ejection fraction. N Engl J Med 357 (2007), 829–830.
181. 181 Richards, A.M., Januzzi, J.L. Jr., Troughton, R.W., Natriuretic peptides in heart failure with preserved ejection fraction. Heart Fail Clin 10 (2014), 453–470.
182. 182 D'Elia, E., Vaduganathan, M., Gori, M., Gavazzi, A., Butler, J., Senni, M., Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail, 2015.
183. 183 Andersen, M.J., Borlaug, B.A., Invasive hemodynamic characterization of heart failure with preserved ejection fraction. Heart Fail Clin 10 (2014), 435–444.
184. 184 Maron, B.A., Cockrill, B.A., Waxman, A.B., Systrom, D.M., The invasive cardiopulmonary exercise test. Circulation 127:10 (2013), 1157–1164.
185. 185 Dorfs, S., Zeh, W., Hochholzer, W., et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 35 (2014), 3103–3112.
186. 186 Borlaug, B.A., Exercise haemodynamics and outcome in patients with dyspnoea. Eur Heart J 35 (2014), 3085–3087.
187. 187 Robbins, I.M., Hemnes, A.R., Pugh, M.E., et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 7 (2014), 116–122.
188. 188 Thadani, U., Parker, J.O., Hemodynamics at rest and during supine and sitting bicycle exercise in normal subjects. Am J Cardiol 41 (1978), 52–59.
189. 189 Thadani, U., West, R.O., Mathew, T.M., Parker, J.O., Hemodynamics at rest and during supine and sitting bicycle exercise in patients with coronary artery disease. Am J Cardiol 39 (1977), 776–783.
190. 190 McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
191. 191 Davis, B.R., Kostis, J.B., Simpson, L.M., et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 118 (2008), 2259–2267.
192. 192 Adamson, P.B., Abraham, W.T., Bourge, R.C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7 (2014), 935–944.
193. 193 Abraham, W.T., Adamson, P.B., Bourge, R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377 (2011), 658–666.
194. 194 Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
195. 195 Massie, B.M., Carson, P.E., McMurray, J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
196. 196 Cleland, J.G., Tendera, M., Adamus, J., Freemantle, N., Polonski, L., Taylor, J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 (2006), 2338–2345.
197. 197 Anand, I.S., Rector, T.S., Cleland, J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4 (2011), 569–577.
198. 198 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
199. 199 Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
200. 200 Edelmann, F., Wachter, R., Schmidt, A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. J Am Med Assoc 309 (2013), 781–791.
201. 201 Bergstrom, A., Andersson, B., Edner, M., Nylander, E., Persson, H., Dahlstrom, U., Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 6 (2004), 453–461.
202. 202 Conraads, V.M., Metra, M., Kamp, O., et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14 (2012), 219–225.
203. 203 van Veldhuisen, D.J., Cohen-Solal, A., Bohm, M., et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53 (2009), 2150–2158.
204. 204 Yamamoto, K., Origasa, H., Hori, M., Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 (2013), 110–118.
205. 205 Hernandez, A.F., Hammill, B.G., O'Connor, C.M., Schulman, K.A., Curtis, L.H., Fonarow, G.C., Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 53 (2009), 184–192.
206. 206 Farasat, S.M., Bolger, D.T., Shetty, V., et al. Effect of beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 105 (2010), 229–234.
207. 207 Bavishi, C., Chatterjee, S., Ather, S., Patel, D., Messerli, F.H., Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 20 (2015), 193–201.
208. 208 Ahmed, A., Rich, M.W., Fleg, J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114 (2006), 397–403.
209. 209 Vamos, M., Erath, J.W., Hohnloser, S.H., Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36 (2015), 1831–1838.
210. 210 Turakhia, M.P., Santangeli, P., Winkelmayer, W.C., et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 64 (2014), 660–668.
211. 211 Thomas, G.R., DiFabio, J.M., Gori, T., Parker, J.D., Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 49 (2007), 1289–1295.
212. 212 Takimoto, E., Champion, H.C., Li, M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5 A prevents and reverses cardiac hypertrophy. Nat Med, 2005.
213. 213 Guazzi, M., Vicenzi, M., Arena, R., Guazzi, M.D., Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124 (2011), 164–174.
214. 214 Borlaug, B.A., Lewis, G.D., McNulty, S.E., et al. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail 8 (2015), 533–541.
215. 215 Hoendermis, E.S., Liu, L.C., Hummel, Y.M., et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36 (2015), 2565–2573.
216. 216 Fukuta, H., Sane, D.C., Brucks, S., Little, W.C., Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005), 357–363.
217. 217 Tavazzi, L., Maggioni, A.P., Marchioli, R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1231–1239.
218. 218 Liu, G., Zheng, X.X., Xu, Y.L., Ru, J., Hui, R.T., Huang, X.H., Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 113 (2014), 1198–1204.
219. 219 Alehagen, U., Benson, L., Edner, M., Dahlstrom, U., Lund, L.H., Association between use of statins and mortality in patients with heart failure and ejection fraction of >/=50. Circ Heart Fail 8 (2015), 862–870.
220. 220 Pandey, A., Parashar, A., Kumbhani, D.J., et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 8 (2015), 33–40.
221. 221 Fleg, J.L., Cooper, L.S., Borlaug, B.A., et al. Exercise training as therapy for heart failure: current status and future directions. Circ Heart Fail 8 (2015), 209–220.
222. 222 Hummel, S.L., Seymour, E.M., Brook, R.D., et al. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 6 (2013), 1165–1171.
223. 223 Roy, D., Talajic, M., Nattel, S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008), 2667–2677.
224. 224 Machino-Ohtsuka, T., Seo, Y., Ishizu, T., et al. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 62 (2013), 1857–1865.
225. 225 McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
226. 226 Filippatos, G., Teerlink, J.R., Farmakis, D., et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 35 (2014), 1041–1050.
227. 227 Kosmala, W., Holland, D.J., Rojek, A., Wright, L., Przewlocka-Kosmala, M., Marwick, T.H., Effect of If-channel inhibition on hemodynamics and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62 (2013), 1330–1338.
228. 228 Ashrafian, H., Pal, N., Sivaswamy, N., et al. The effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation, 2015.